Ba Tai (巴泰)巴泰
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 成都倍特药业有限公司Chinese legal name: 成都倍特药业有限公司
主要成分Active Ingredients
- 格拉司琼Gela Siqiong
药物知识说明
格拉司琼是一种在国家药监局注册认定的药品。该药品含有格拉司琼-cba563fe等成分。
该药品关联的活性成分包括：格拉司琼Gela Siqiong。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：成都倍特药业有限公司Chinese legal name: 成都倍特药业有限公司。
您可以探索含有相同成分的其他药品：格拉司琼-cba563fe成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 巴泰) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 格拉司琼Gela Siqiong.
Manufacturers recorded for this product: 成都倍特药业有限公司Chinese legal name: 成都倍特药业有限公司.
Explore other medicines containing the same ingredient: 格拉司琼 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 巴泰Recorded Chinese name: 巴泰
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 50ml：格拉司琼3mg，氯化钠0.45g。Recorded Chinese description: 50ml：格拉司琼3mg，氯化钠0.45g。
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 成都倍特药业有限公司Chinese legal name: 成都倍特药业有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20030370
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20030370
Manufacturer
Chinese legal name: 成都倍特药业有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20030370
生产企业
成都倍特药业有限公司(国产)
适应症
用于放疗、细胞毒类药物化疗引起的恶心和呕吐。
用法用量
静脉滴注，成人用量通常为3mg，于治疗前30分钟给药，大多数病人只需给药一次，对于恶心和呕吐的预防作用便可超过24小时，必要时可增加给药次数1-2次，但每日最高剂量不应超过9mg。
不良反应
常见的副作用为头痛、倦怠、发热，便秘、偶有短暂性无症状肝转氨酶增加。上述反映轻微，无须特殊处理即可恢复。
禁忌
l、肠梗阻患者禁用。
2、对本品过敏者禁用。
注意事项
1、由于本品可减缓消化道运动，故消化道运动障碍患者使用本品时应严密观察。
2、本品不应与其它药物混合使用。
贮藏
遮光，密闭保存。
规格
50ml：格拉司琼3mg，氯化钠0.45g。
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.